{"id":"W4253021856","doi":"10.1200/jco.2015.33.15_suppl.tps5610","title":"The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; MEK inhibitor; Internal medicine; Oncology; Clinical endpoint; KRAS; Chemotherapy; Cancer; MAPK/ERK pathway; Clinical trial; Kinase; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001826404,0.001271295,0.001439604,0.0003746398,0.0003652843,0.0007572626,0.0007224342,0.001501375,0.005016659],"category_scores_gemma":[0.001061838,0.000687307,0.001464409,0.000313191,0.0009711013,0.0009250776,0.0003829344,0.00305026,0.000825829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008180119,"about_ca_system_score_gemma":0.001283152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007997047,"about_ca_topic_score_gemma":0.003637319,"domain_scores_codex":[0.9996227,0.0002029864,0.00001825538,0.00005118179,0.00003083272,0.00007396921],"domain_scores_gemma":[0.9993765,0.0001430752,0.0001285243,0.00004930753,0.0000297882,0.0002728697],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.938028,0.01965282,0.003837882,0.0008099591,0.0007040629,0.0001086027,0.0001283451,0.0008259314,0.007286787,0.0002268907,0.002056457,0.02633426],"study_design_scores_gemma":[0.8976589,0.09433041,0.004747969,0.00003933386,0.0003102697,0.00008585867,0.00003763934,0.000537932,0.0007718608,0.0001591011,0.001302124,0.00001862823],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861839,0.002306866,0.0005296141,0.001044161,0.0002543446,0.005237213,0.002016932,0.000102088,0.002324874],"genre_scores_gemma":[0.9813755,0.001634703,0.002017004,0.001800144,0.000190911,0.006254701,0.002630148,0.00002781314,0.004069123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005016659,"threshold_uncertainty_score":0.0167824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1472523300534662,"score_gpt":0.4477943129960404,"score_spread":0.3005419829425742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}